Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alphamab OncologyFRA:3NK +0.57%55 PB Ratio is 4.11 as of Aug. 20, 2026, which is 11% above its 10-year median of 3.69. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review. Among 1,214 Biotechnology companies, Alphamab Oncology ranks worse than 63.76% on this metric.
The historical rank and industry rank for Alphamab Oncology's PB Ratio or its related term are showing as below:
FRA:3NK'
s PB Ratio Range Over the Past 10 Years
Min: 1.14 Med: 3.69 Max: 9.12
Current: 4.28
During the past 9 years, Alphamab Oncology's highest PB Ratio was 9.12. The lowest was 1.14. And the median was 3.69.
FRA:3NK's PB Ratio is ranked worse than 63.76% of 1214
companies
in the Biotechnology industry
Industry Median: 2.94
vs FRA:3NK: 4.28
During the past 12 months, Alphamab Oncology's average Book Value Per Share Growth Rate was -4.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Alphamab Oncology was 443.00% per year. The lowest was -15.00% per year. And the median was -6.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alphamab Oncology PB Ratio Related Terms
Alphamab Oncology PB Ratio Historical Data
* Premium members only.
The historical data trend for Alphamab Oncology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alphamab Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alphamab Oncology (FRA:3NK) has a PB Ratio of 4.11 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alphamab Oncology and its competitors. This is 11% above median its historical median of 3.69. Over the past decade, Alphamab Oncology's PB Ratio has ranged from 1.14 to 9.12. According to the industry distribution chart, Alphamab Oncology ranks #774 out of 1214 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Alphamab Oncology's PB Ratio too high?
Alphamab Oncology's current PB Ratio of 4.11 is 11% above median its 10-year median of 3.69. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 9.12. The Biotechnology industry median PB Ratio is 2.94. Alphamab Oncology's value of 4.11 is 39.8% above this industry median. Based on the distribution chart, Alphamab Oncology ranks #774 out of 1214 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alphamab Oncology ranks #774 out of 1214 companies for PB Ratio. This places Alphamab Oncology in the lower half of its industry. The industry median PB Ratio is 2.94. Alphamab Oncology's value of 4.11 is 39.8% above this benchmark. Historically, Alphamab Oncology's own PB Ratio has ranged from 1.14 to 9.12 over the past decade. While the company's 10-year median is 3.69 vs. the industry median of 2.94, Alphamab Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,214 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alphamab Oncology's current PB Ratio of 4.11 is 39.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alphamab Oncology and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alphamab Oncology's current PB Ratio is 4.11, which is 11% above median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current PB Ratio of 4.11. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current PB Ratio is 4.11, which is 11% above median its 10-year median of 3.69 and 39.8% above the Biotechnology industry median of 2.94. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current PB Ratio is 4.11 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?
Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued.
The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.
Key valuation signals for FRA:3NK:
PB Ratio: 4.11 (11% above median its 10-year median of 3.69)
GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
Industry Position: 39.8% above the Biotechnology median (#774 of 1214)
No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score
Get the complete analysis for FRA:3NK
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3NK has been successfully added to your 
